Receptor-mediated therapies are transforming oncology by enabling more precise targeting of cancer biology, and this webinar brings together experts across preclinical research, flow cytometry, clinical development and regulatory strategy to outline what it takes to design, validate and advance next-generation receptor-based treatments. Speakers will cover the evolving preclinical landscape, including modern tumor models and ligand engineering, followed by how flow cytometry supports receptor expression, functional activity and mechanism confirmation from discovery through early clinical trials.
The session then explores clinical and regulatory lessons from current and emerging receptor-targeted therapies, highlighting how receptor biology translates to patient impact and how expectations are shifting for novel mechanisms. The program concludes with practical guidance for developers, including considerations tied to the FDA’s Plausible Mechanism Pathway and strategies for building development plans that balance innovation with safety and regulatory readiness.
SPEAKERS
Erin Trachet
Senior Director, Scientific Engagement, TD2 Oncology
Erin Trachet has devoted her career to oncology research with a focus on pharmacology. She has worked in both industry and the CRO space for more than 26 years. In industry, she was part of several successful small-molecule programs, including Palbociclib (Pfizer’s CDK4/6 inhibitor) and Dacomitinib (Pfizer’s pan-EGFR inhibitor). At TD2, she developed a collaborative, scientifically engaging environment in which the Sponsor, Scientific Engagement and the Execution Team all work together to drive the Sponsor’s program forward.
Jennifer Stewart, PhD
VP Flow Cytometry Strategy, TD2 Oncology
Dr. Jennifer Stewart has 20+ years of experience with flow cytometry in academic, nonclinical and clinical settings. Throughout her career, she has had the opportunity to interface with clients to gain an understanding of the evolving demands for the technology in drug development. Her mission is to be at the cutting edge of the field, knowing that TD2’s services can help create treatments for millions worldwide who currently suffer from disease. This effort is supplemented through collaborations with other experts on research projects, publishing manuscripts, organizing workshops and speaking at symposiums.
Jennifer is currently serving as the Vice President of Flow Cytometry Strategy at TD2 Oncology and is involved in interpreting and reporting for the various flow cytometry projects. In addition, she is the Co-chair for the AAPS Flow Cytometry Action Programming Committee and has served as a Guest Editor for Cytometry Part B: Clinical Cytometry and as a Scientific Reviewer for several high-profile journals.
Alan Miller, MD, PhD
Chief Medical Officer, TD2 Oncology
Dr. Alan Miller obtained his PhD at Roswell Park (SUNY) and his MD from the University of Miami School of Medicine. Trained as a Medical Oncologist, he was also the Associate Senior Vice President for Health Sciences for Tulane Cancer Center, where he navigated the challenges of rebuilding and re-establishing the university and hospital following Hurricane Katrina. He also served as Cancer Center Director of the Baylor Sammons Cancer Center, where he brought together a not-for-profit healthcare system and private oncology practices to form an oncology network across North Texas. Additionally, Dr. Miller built a larger system-wide oncology network while at SCL Health and established a system-wide clinical trials infrastructure for a multi-state healthcare system. He also serves as a Board Member for the American Cancer Society, Denver and the Rocky Mountain Oncology Society.
